NR 585NP Week 6 Evidence Synthesis Example

Evidence Synthesis: Self-Monitoring Lowers Blood Pressure When Someone Acts on the Readings, and the Same Evidence Will Not Say That Lending Cuffs Does

Student Name

College of Nursing, Chamberlain University

NR 585NP: Research Methods and Evidence-Based Practice for Advanced Nursing Practice

Instructor Name

Month Day, Year

Evidence Synthesis: Self-Monitoring Lowers Blood Pressure When Someone Acts on the Readings, and the Same Evidence Will Not Say That Lending Cuffs Does

Two Sentences, Printed Together

Supported: for primary care adults whose hypertension is uncontrolled, self-measured blood pressure monitoring combined with a clinician or pharmacist adjusting medication based on the readings lowers office systolic pressure by a few mm Hg, and sometimes more, over 6 to 12 months compared with office-based care.

Refused: the same evidence does not support saying that lending home cuffs, without anyone acting on the readings, lowers blood pressure, and it does not support saying that self-monitoring reduces strokes or heart attacks.

Everything below explains the boundary between those two sentences.

Finding 1: Self-Monitoring With Clinician Action Lowers Blood Pressure

Across the set, trials in which home readings were used to change medication found lower office systolic pressure than usual care. The individual patient data meta-analysis found a reduction at 12 months, and an effect that grew with the intensity of the accompanying support (Tucker et al., 2017). TASMINH4, in English general practice, found differences of roughly 3 and 5 mm Hg after a year for self-monitoring and telemonitoring arms used to guide titration (McManus et al., 2018). The HyperLink trial, in which pharmacists reviewed transmitted home readings and adjusted medication, found larger reductions over the first year that narrowed after the support ended (Margolis et al., 2013).

Finding 2: Self-Monitoring Alone Has Little Effect

Where home monitoring was used without a structured plan for acting on readings, effects were small or absent. Uhlig et al. (2013) found a modest reduction at 6 months for self-monitoring alone that was not clear at 12 months, while self-monitoring with additional support produced larger and more lasting differences. Tucker et al. (2017) reported that self-monitoring with no added intervention produced little change in blood pressure.

Giving Disagreement a Cause

The trials disagree on the size of the effect, from about 3 mm Hg in TASMINH4 to more than double that in HyperLink. The appraisals point to a cause rather than to one trial being better than the other. HyperLink added pharmacist case management with frequent contact; TASMINH4 relied on the practice's own doctors and a simpler titration schedule. HyperLink's effect also shrank after the pharmacist support stopped. The difference is in the intensity of what was done with the readings, not in the cuffs. That pattern matches Finding 2: the more someone acts on readings, the larger the effect.

Finding 3: The Effect Fades When Support Stops

The longest follow-up in the set came from HyperLink, where the gap between groups was largest while pharmacists were managing medication and smaller after their support ended (Margolis et al., 2013). The meta-analyses mostly report outcomes at 6 and 12 months and say little about what happens later. Taken together, the set suggests the benefit depends on the support continuing. A practice that runs a time-limited program should expect some of the effect to fade.

How the Evidence Was Grouped

The evidence matrix from earlier weeks listed each study in a row. For this synthesis, I sorted the rows by what was done with the readings: nothing structured, clinician titration at usual visits, or active management by a pharmacist or nurse between visits. Sorting this way, rather than by year or country, made the pattern in Finding 2 visible: effects rose from the first group to the third. Only then was each finding written, with every study that supports it cited in the same sentence.

Certainty That Rests on Design

Certainty for the supported claim is moderate. It rests on randomized trials and two meta-analyses that agree in direction. It is not high, because the trials could not blind participants or clinicians, and because effect sizes vary with the intensity of support. In the terms of the GRADE approach, the evidence starts high because it comes from randomized trials and is rated down for risk of bias from lack of blinding and for inconsistency in effect size (Guyatt et al., 2008).

Certainty for any claim about strokes or heart attacks is very low from this set, because none of the trials was large or long enough to measure them. The link from blood pressure to events comes from a different body of evidence, which the recommendation can mention but should not borrow certainty from.

Whose Patients This Reaches

The trials were mostly in primary care in the United States and United Kingdom, with adults willing to join a trial and, in many, to use a phone or internet connection to send readings. Several used 140/90 as the target; Cedar uses 130/80. No trial in the set had a US registered nurse titrating by standing order. The result therefore reaches Cedar's patients who are able and willing to monitor at home, with the caveat that a nurse-led version resembles, without matching, the pharmacist-led and doctor-led versions tested. Patients without a portal account, or who struggle with the cuff, are less represented in the trials, and the effect for them is less certain.

What the Synthesis Adds Beyond Each Paper

No single paper in the set answers Cedar's question, which combines a 130/80 target, a nurse and a US primary care practice. Together they show that the active ingredient is acting on readings, which no single trial could show on its own. That finding redirects the colleague's original proposal from buying cuffs to building a way for someone to use the readings.

What Remains Unknown

The set cannot say how long the effect lasts after support ends, beyond HyperLink's suggestion that it narrows. It cannot say whether a nurse under protocol achieves the pharmacist's effect. It cannot say how many of Cedar's 268 patients would take part. These gaps shape next week's recommendation: they argue for a pilot rather than a practice-wide change.

What This Means for the Original Proposal

The colleague's proposal to lend cuffs was a reasonable instinct: the trials do show that home readings can help. The synthesis narrows it. Cuffs are the cheap part; the work is in someone reviewing readings and changing medication on a schedule. Any program at Cedar that buys cuffs without funding that work would, on this evidence, be expected to change little.

Limits of the Synthesis

The set is limited to English-language trials since 2008, from three databases. Two of the 12 trials were small. I did not pool results myself; the effect sizes reported here come from the published papers and meta-analyses.

References

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924-926. https://doi.org/10.1136/bmj.39489.470347.AD

Margolis, K. L., Asche, S. E., Bergdall, A. R., Dehmer, S. P., Groen, S. E., Kadrmas, H. M., Kerby, T. J., Klotzle, K. J., Maciosek, M. V., Michels, R. D., O'Connor, P. J., Pritchard, R. A., Sekenski, J. L., Sperl-Hillen, J. M., & Trower, N. K. (2013). Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: A cluster randomized clinical trial. JAMA, 310(1), 46-56. https://doi.org/10.1001/jama.2013.6549

McManus, R. J., Mant, J., Franssen, M., Nickless, A., Schwartz, C., Hodgkinson, J., Bradburn, P., Farmer, A., Grant, S., Greenfield, S. M., Heneghan, C., Jowett, S., Martin, U., Milner, S., Monahan, M., Mort, S., Ogburn, E., Perera-Salazar, R., Shah, S. A., ... Hobbs, F. D. R. (2018). Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): An unmasked randomised controlled trial. The Lancet, 391(10124), 949-959. https://doi.org/10.1016/S0140-6736(18)30309-X

Tucker, K. L., Sheppard, J. P., Stevens, R., Bosworth, H. B., Bove, A., Bray, E. P., Earle, K., George, J., Godwin, M., Green, B. B., Hebert, P., Hobbs, F. D. R., Kantola, I., Kerry, S. M., Leiva, A., Magid, D. J., Mant, J., Margolis, K. L., McKinstry, B., ... McManus, R. J. (2017). Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLOS Medicine, 14(9), e1002389. https://doi.org/10.1371/journal.pmed.1002389

Uhlig, K., Patel, K., Ip, S., Kitsios, G. D., & Balk, E. M. (2013). Self-measured blood pressure monitoring in the management of hypertension: A systematic review and meta-analysis. Annals of Internal Medicine, 159(3), 185-194. https://doi.org/10.7326/0003-4819-159-3-201308060-00008